News | Hypertension | February 13, 2017

FDA Grants Expedited Access Pathway for MobiusHD to Treat Resistant Hypertension

EAP program designed to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments

February 13, 2017 — Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD device for the treatment of resistant hypertension.

VDI was also one of only nine companies chosen for the FDA’s Early Feasibility Study Investigational Device Exemptions (IDE) Pilot Program in 2012. The Pilot Program enables companies to conduct smaller-scale studies under the guidance of the FDA in the United States in order to meet the requirements for an earlier pathway toward approval.

The EAP program is a focused initiative, recently launched by FDA, to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments. The program was designed for certain medical devices that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases or conditions, such as resistant hypertension, that may be subject to premarket approval applications.

The MobiusHD System, a minimally-invasive system for the treatment of resistant hypertension, capitalizes on the ability of the body’s baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby amplify the body’s natural response to lower blood pressure through vasodilation.

“Among the benefits of the technology are that it may reduce ambulatory blood pressure in resistant hypertension patients who have not benefited from other device or drug based treatments,” said Prof. Brian Williams, co-principal investigator of the CALM II worldwide clinical trial, and NIHR University College London Hospitals Biomedical Research Centre Director. “The Mobius HD technology may provide an important solution for those patients. We are enthusiastic about the product’s potential as we have seen tremendous results in early studies in the U.S. and Europe.”

“In clinical practice, we regularly observe that despite multiple treatment modalities, many patients are still not responding adequately to therapy, whether it be lifestyle changes, multiple drug therapy, or the combination of each. This lack of response significantly increases their risk of further complications,” said Gregg Stone, M.D., co-principal investigator of the CALM II worldwide clinical trial and director of cardiovascular research and education for Columbia University Medical Center/New York-Presbyterian Hospital and co-director of medical research and education at the Cardiovascular Research Foundation.

“The EAP Designation for the MobiusHD device comes at a critical time for hypertension physicians, who are actively looking for treatment options for patients who are not adequately managed with current guideline-directed therapies,” said George Bakris, M.D., chairman of the worldwide CALM II clinical trial hypertension committee and director, ASH Comprehensive Hypertension Center, The University of Chicago School of Medicine.

For more information: www.vasculardynamics.com

Related Content

Sponsored Content | Videos | Cath Lab| March 28, 2017
MDBuyline analyst Tom Watson shares some of the most important trends in cardiac technology he saw at the 2017 Americ
Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors| March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Philips Azurion angiography system, FFR for STEMI
Feature | Cath Lab| March 27, 2017
March 27, 2017 — Patients experiencing a major heart attack often have more than one clogged artery, but under curren
online lifestyle intervention, systolic blood pressure, hypertension, ACC.17, clinical study
News | Hypertension| March 27, 2017
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg...
Sponsored Content | Videos | Heart Valve Technology| March 24, 2017
Michael Reardon, M.D., professor of cardiothoracic surgery at Houston Methodist DeBakey Heart and Vascular Center, di
Philips, cardiology solutions, ACC.17, Azurion angiography system, iFR outcomes results, IntelliSpace Cardiovascular
News | Cardiac Imaging| March 24, 2017
At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad...
Sponsored Content | Videos | FFR Catheters| March 23, 2017
Justin Davies, MBBS, of Imperial College London, and Matthias Götberg, M.D, Ph.D., of Skane University Hospital, deta
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT)| March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies| March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low do
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
Overlay Init